本文選題：骨髓增生異常綜合癥　切入點(diǎn)：甲基化　出處：《新疆醫(yī)科大學(xué)》2017年碩士論文　論文類(lèi)型：學(xué)位論文

【摘要】：目的:研究骨髓增生異常綜合征(myelodysplastic syndrome,MDS)患者FHIT、SOCS1、DAPK和P15基因甲基化的表達(dá)及其臨床意義。方法:采用甲基化特異性方法檢測(cè)骨髓標(biāo)本中FHIT、SOCS1、DAPK和P15基因的甲基化狀態(tài),分析甲基化狀態(tài)與臨床相關(guān)性。結(jié)果:67例MDS患者FHIT、SOCS1、DAPK和P15基因甲基化頻率分別為52.2%(35/67)、47.8%(32/67)、35.8%(24/67)和37.3%(25/67),較對(duì)照組增高明顯(P0.05);相對(duì)低危組與相對(duì)高危組患者相比較,P15、SOCS1甲基化頻率明顯增高(P0.05);四種基因中高于2個(gè)基因甲基化率對(duì)于相對(duì)高危組明顯高于相對(duì)低危組患者(P0.05);67例患者中位生存時(shí)間為18(13.3-22.7)月;基因甲基化陽(yáng)性患者生存時(shí)間明顯短于陰性患者(15個(gè)月與21個(gè)月,P0.05);相對(duì)低危組中SOCS1基因甲基化患者生存時(shí)間短于非甲基化患者(P0.05)。相對(duì)高危組中SOCS1、P15及≥2個(gè)基因甲基化患者生存時(shí)間明顯短于非甲基化患者(P0.05)。多因素分析顯示SOCS1及P15基因甲基化是MDS患者預(yù)后不良的影響因素。結(jié)論:FHIT、SOCS1、DAPK和P15基因甲基化在MDS中具有一定的影響;SOCS1、P15基因甲基化是MDS患者預(yù)后不良的影響因素。
[Abstract]:Objective: To study the myelodysplastic syndrome (myelodysplastic syndrome, MDS) in patients with FHIT, SOCS1, DAPK expression and methylation of P15 gene and its clinical significance. Methods: using methyl FHIT, specific method for the detection of SOCS1 in bone marrow samples, methylation of DAPK gene and P15 gene, methylation status and clinical correlation analysis. Results: 67 cases of MDS patients with FHIT, SOCS1, DAPK and P15 gene methylation frequencies were 52.2% (35/67), 47.8% (32/67), 35.8% (24/67) and 37.3% (25/67), significantly higher than the control group (P0.05); patients with relatively low risk group and the relatively high risk group compared to P15, SOCS1 methyl the frequency increased significantly (P0.05) higher than 2; gene methylation rate for the relatively high risk group was significantly higher than the relatively low risk group were four (P0.05) gene in 67 patients; the median survival time was 18 months (13.3-22.7); gene methylation positive patients had shorter survival time than those with Who (15 months and 21 months, P0.05); relative survival time in patients with SOCS1 gene methylation in the low risk group is shorter than the patients without methylation (P0.05). The relatively high risk group of SOCS1, P15 and more than 2 gene methylation in patients with survival time was shorter in patients with non methylation (P0.05). Factor analysis showed that SOCS1 and P15 gene methylation is the influencing factors of poor prognosis of patients with MDS. Conclusion: FHIT, SOCS1, DAPK and methylation of P15 gene has a certain effect in MDS; SOCS1, P15 gene methylation is the influencing factors of poor prognosis of patients with MDS.

【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R551.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 秦晨琛;甘思林;萬(wàn)鼎銘;孫玲;陳勝梅;陳紹倩;王芳;劉林湘;劉延方;謝新生;馬杰;孫慧;;骨髓增生異常綜合征轉(zhuǎn)化的急性髓系白血病52例臨床觀察[J];白血病·淋巴瘤;2016年05期

2 任衍鋼;白冠軍;宋玉奇;衛(wèi)紅萍;;表觀遺傳學(xué)的起源與發(fā)展[J];生物學(xué)通報(bào);2016年03期

3 張薇;邵宗鴻;;骨髓增生異常綜合征異常造血克隆研究進(jìn)展[J];中國(guó)實(shí)用內(nèi)科雜志;2015年02期

4 徐鋼;孟祥寧;傅松濱;;癌癥中表觀遺傳學(xué)的作用[J];國(guó)際遺傳學(xué)雜志;2014年04期

5 張耀;宋陸茜;吳凌云;常春康;李曉;;骨髓增生異常綜合征患者p15~(INK4B)基因甲基化與疾病進(jìn)展的Meta分析[J];腫瘤防治研究;2013年06期

6 鄧銀芬;張磊;張秀群;胡明秋;戴丹;張學(xué)忠;徐燕麗;;骨髓增生異常綜合征患者血漿DNA中FHIT基因啟動(dòng)子區(qū)甲基化狀態(tài)及地西他濱的去甲基化作用[J];中國(guó)實(shí)驗(yàn)血液學(xué)雜志;2012年05期

7 邵宗鴻;張薇;;骨髓增生異常綜合征去甲基化治療進(jìn)展[J];臨床血液學(xué)雜志;2011年03期

8 王淋淋;高沖;陳寶安;;MDS轉(zhuǎn)化為AML機(jī)制的研究進(jìn)展[J];中國(guó)實(shí)驗(yàn)血液學(xué)雜志;2011年01期

9 姚冬明;錢(qián)軍;許文榮;林江;江云偉;費(fèi)霞;韓蘭秀;王雅麗;岑建農(nóng);陳子興;;骨髓增生異常綜合征患者FHIT基因啟動(dòng)子甲基化改變[J];中華醫(yī)學(xué)遺傳學(xué)雜志;2008年01期

10 姚冬明;林江;錢(qián)軍;陳子興;王雅麗;許文榮;韓蘭秀;盛曉靜;楊小飛;;骨髓增生異常綜合征患者中死亡相關(guān)蛋白激酶基因的啟動(dòng)子甲基化改變[J];中華血液學(xué)雜志;2009年11期

，

本文編號(hào)：1631642